Spero Therapeutics, Inc.

SPRO ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2017 FY2016
Assets
Cash & Equivalents $87.3M $10.3M
Accounts Receivable — —
Inventory — —
Total Current Assets $92.1M $11.9M
Property, Plant & Equipment $1.2M $1.5M
Goodwill — —
Intangible Assets (Excl. Goodwill) — —
Total Assets $93.5M $13.8M
Liabilities
Accounts Payable $3.5M $1.1M
Total Current Liabilities $8.2M $6.9M
Long-Term Debt — —
Total Liabilities $8.5M $7.4M
Stockholders' Equity
Retained Earnings $-96.8M $-45.4M
Total Stockholders' Equity $84.6M $-45.4M
← Newer Page 2 of 2 Older →